Welcome to our dedicated page for Mustang Bio news (Ticker: MBIO), a resource for investors and traders seeking the latest updates and insights on Mustang Bio stock.
Mustang Bio, Inc. (Nasdaq: MBIO) is a clinical-stage biopharmaceutical company developing cell therapies for difficult-to-treat cancers, and its news flow reflects both scientific progress and capital markets activity. The company focuses on CAR T-cell therapies and an HSV-1 oncolytic virus, with programs aimed at malignant glioma, recurrent glioblastoma (GBM), high-grade astrocytomas, and related brain tumors.
News about Mustang Bio often centers on pipeline milestones, including updates on MB-101, an IL13Rα2-targeted CAR T-cell therapy, and MB-108, an HSV-1 oncolytic virus. The company has reported U.S. Food and Drug Administration Orphan Drug Designations for MB-108 in malignant glioma and MB-101 in recurrent diffuse and anaplastic astrocytoma and glioblastoma. Mustang Bio also highlights the MB-109 regimen, which combines MB-101 and MB-108 to reshape the tumor microenvironment and potentially enhance CAR-T activity in recurrent GBM and high-grade astrocytomas.
Investors following MBIO news will also see listing and financing developments, such as reverse stock split announcements, Nasdaq compliance updates on minimum bid price and stockholders’ equity requirements, and details of public offerings and warrant exercises. These items provide context on Mustang Bio’s access to capital and its efforts to maintain its Nasdaq Capital Market listing.
This news page aggregates Mustang Bio’s press releases and related coverage, giving readers a single place to review regulatory designations, clinical trial updates, facility and operational changes, and securities offerings. For those tracking MBIO, revisiting this page can help monitor how Mustang Bio’s cell therapy programs and corporate actions evolve over time.
Mustang Bio (Nasdaq: MBIO) reported advancements in its CAR T cell therapy portfolio, highlighting the ongoing Phase 1/2 clinical trial of MB-106 for B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The company met enrollment targets and aims to provide safety and efficacy data in 2023. MB-106 shows high efficacy with a 100% overall response rate in Waldenstrom macroglobulinemia patients. Additionally, Mustang plans to file an IND for the combination therapy MB-109 for glioblastoma in 2023, and it anticipates further clinical advancements in its CAR T platform.
Mustang Bio (MBIO) announced its Q3 2022 financial results, highlighting significant advancements in its cell and gene therapy portfolio. The company treated its first patient in a Phase 1/2 trial for MB-106, targeting B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The ongoing trial at Fred Hutch continues to show promising results, with a 100% complete response rate in Waldenstrom macroglobulinemia patients. Financially, Mustang reported a net loss of $19 million for the quarter, with cash reserves decreasing to $92.4 million.
Mustang Bio announced promising interim results from the MB-106 Phase 1/2 clinical trial targeting Waldenstrom macroglobulinemia (WM) and other B-cell non-Hodgkin lymphomas (B-NHLs). The trial reported a 100% overall response rate (ORR) and a 75% complete response (CR) in various hematologic malignancies, with two WM patients achieving a complete response. The FDA granted Orphan Drug Designation for MB-106, enhancing its potential for expedited development. The data will be presented at the IWWM-11 workshop in Madrid, Spain, highlighting the therapy's efficacy and safety profile.
Mustang Bio, Inc. (Nasdaq: MBIO) has initiated a multicenter, open-label Phase 1/2 clinical trial for MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia (CLL). The trial marks a significant milestone, following promising interim results from 28 patients, showing a 96% overall response rate and a 75% complete response rate. The treatment demonstrated a favorable safety profile with no severe cases of cytokine release syndrome or neurotoxicity. Further efficacy data will be reported in Q4 2022.
Mustang Bio (NASDAQ: MBIO), a clinical-stage biopharmaceutical firm, has announced CEO Manuel Litchman will participate in two investor conferences in New York City. The H.C. Wainwright 24th Annual Global Investment Conference will occur on September 12, 2022, featuring a corporate update and one-on-one meetings. A presentation will be webcasted for 30 days. Additionally, Mustang will engage in a panel at the Cantor Cell & Gene Therapy Conference on September 15, 2022. Mustang specializes in cell and gene therapies targeting various cancers and rare diseases.
Mustang Bio, Inc. (NASDAQ: MBIO) announced its financial results for Q2 2022, reporting a cash balance of $108.4 million, down from $123.2 million in Q1 2022. The company highlighted significant milestones, including favorable interim Phase 1/2 data for its CAR T therapy MB-106 for B-cell cancers, achieving an overall response rate of 96%. Additionally, FDA granted Orphan Drug Designation to MB-106 for Waldenstrom macroglobulinemia. R&D expenses increased to $15.2 million, with a net loss of $19.1 million for the quarter. Mustang anticipates advancing its gene therapy programs in 2023.
Mustang Bio (NASDAQ: MBIO) announced the successful administration of LV-RAG1, an ex vivo lentiviral gene therapy, to the first patient in a Phase 1/2 trial for treating RAG1-SCID, a severe genetic immunodeficiency. This significant milestone reflects the potential of MB-110, licensed from LUMC, to offer new hope for SCID patients. The treatment resulted in a functioning immune system, marking a positive development in Mustang's clinical pipeline. The company anticipates further advancements and plans to initiate a pivotal Phase 2 trial for MB-107 in the latter half of the year.
Mustang Bio has announced that the FDA has granted Orphan Drug Designation to MB-106, a CAR T cell therapy for Waldenstrom macroglobulinemia, a rare B-cell non-Hodgkin lymphoma. This designation provides benefits like tax credits and seven years of market exclusivity. The multicenter Phase 1/2 trial evaluating MB-106's safety and efficacy for relapsed/refractory B-NHL and CLL is now open for enrollment. Data presented at a recent congress showed a 96% overall response rate and a potential for outpatient administration, marking significant progress in addressing high unmet medical needs.
Mustang Bio, Inc. (NASDAQ: MBIO) announced promising interim data from a Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-NHLs and CLL. The therapy demonstrated a 94% overall response rate and a 78% complete response rate in patients with follicular lymphoma. Additionally, it achieved a 100% overall response rate in other B-cell malignancies. The trial showcases a favorable safety profile, making MB-106 a viable outpatient treatment option. Enrollment for the study remains open.
Mustang Bio (NASDAQ: MBIO) has announced encouraging interim results from a Phase 1/2 clinical trial for its gene therapy MB-107, aimed at treating X-linked severe combined immunodeficiency (XSCID). The trial included 23 infants, all of whom are alive and have shown complete hematopoietic recovery without signs of malignant transformation at a median follow-up of 2.6 years. The company plans to initiate a pivotal Phase 2 trial later this year, further validating the therapy's safety and efficacy.